Galectin-1-mediated MET/AXL signaling enhances sorafenib resistance in hepatocellular carcinoma by escaping ferroptosis

Sorafenib, a small-molecule inhibitor targeting several tyrosine kinase pathways, is the standard treatment for advanced hepatocellular carcinoma (HCC). However, not all patients with HCC respond well to sorafenib, and 30% of patients develop resistance to sorafenib after short-term treatment. Galec...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Tung-Wei, Su, Yen-Hao, Chen, Hsin-An, Liao, Po-Hsiang, Shen, Shih Chiang, Tsai, Kuei-Yen, Wang, Tzu-Hsuan, Chen, Alvin, Huang, Chih-Yang, Shibu, Marthandam Asokan, Wang, Wan-Yu, Shen, Shing-Chuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373977/
https://www.ncbi.nlm.nih.gov/pubmed/37433225
http://dx.doi.org/10.18632/aging.204867

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373977/
https://www.ncbi.nlm.nih.gov/pubmed/37433225
http://dx.doi.org/10.18632/aging.204867

Ejemplares similares